2.2亿元!翰森购入“医药一哥”一款1类新药

生物药大时代
Dec 29, 2025

声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议。12月28日晚,翰森制药发布公告宣布,公司与恒瑞医药订立许可协议。根据许可协议,翰森制药获得恒瑞医药的独家许可,以于中国(不含香港、澳门及台湾)开发、生产和商业化SHR6508,并有权根据许可协议条款进一步分许可。翰森制药将向恒瑞医药支付3000万元...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10